Meet our executive team
Fredrik Palm
Chief Executive Officer since 2022
Born: 1975
Education: Studies in engineering at Stockholm Institute of Technology (STI) and studies in business management and strategic marketing at Stockholm School of Economics and IHM Business School.
Previous positions: CEO of ContextVision 2019–2022 and Vice President of the Medical Imaging business area prior to that. Over twenty years experience in international commercial operations and business development within medtech and life science business, for example at Bactiguard and Waters Corporation.
Shareholding as of 28 February 2025: 91,049 shares and 688,729 options.
Education: Studies in engineering at Stockholm Institute of Technology (STI) and studies in business management and strategic marketing at Stockholm School of Economics and IHM Business School.
Previous positions: CEO of ContextVision 2019–2022 and Vice President of the Medical Imaging business area prior to that. Over twenty years experience in international commercial operations and business development within medtech and life science business, for example at Bactiguard and Waters Corporation.
Shareholding as of 28 February 2025: 91,049 shares and 688,729 options.
Ann-Charlotte Linderoth
Chief Financial Officer since 2022
Born: 1972
Education: Bachelor of Science in Business Administration and Economics from Stockholm University.
Previous positions: CFO at ContextVision during 2015 - 2022, and Financial Officer prior to that. Linderoth has thirty years of experience in economics and accounting, mainly from companies operating in the medtech field.
Shareholding as of 28 February 2025: 73,000 shares and 318,784 options.
Education: Bachelor of Science in Business Administration and Economics from Stockholm University.
Previous positions: CFO at ContextVision during 2015 - 2022, and Financial Officer prior to that. Linderoth has thirty years of experience in economics and accounting, mainly from companies operating in the medtech field.
Shareholding as of 28 February 2025: 73,000 shares and 318,784 options.
Magnus Aurell
Chief Commercial Officer since 2022
Born: 1964
Education: Master of Science in Biophysics from Uppsala University.
Previous positions: Vice President at ContextVision, Digital Pathology 2020–2022. Business Area Manager, AMRA Medical. CEO at EXINI Diagnostics. Aurell has over thirty years of experience in the medtech and pharmaceuticals industries. His main focus has been on international commercialisation and business development.
Shareholding as of 28 February 2025: 5,000 shares and 318,784 options.
Education: Master of Science in Biophysics from Uppsala University.
Previous positions: Vice President at ContextVision, Digital Pathology 2020–2022. Business Area Manager, AMRA Medical. CEO at EXINI Diagnostics. Aurell has over thirty years of experience in the medtech and pharmaceuticals industries. His main focus has been on international commercialisation and business development.
Shareholding as of 28 February 2025: 5,000 shares and 318,784 options.
Emelie Edvigsson
Chief Operating Officer since 2022
Born: 1983
Education: Biomedical scientist degree from Umeå University.
Previous positions: Synlab-Medilab, 2017–2021, Head of Clinical Histopathology and Cytology. Fifteen years’ experience in laboratory operations and management, has worked as a biomedical scientist in both public healthcare and the private sector.
Shareholding as of 28 February 2025: 0 shares and 318,784 options.
Education: Biomedical scientist degree from Umeå University.
Previous positions: Synlab-Medilab, 2017–2021, Head of Clinical Histopathology and Cytology. Fifteen years’ experience in laboratory operations and management, has worked as a biomedical scientist in both public healthcare and the private sector.
Shareholding as of 28 February 2025: 0 shares and 318,784 options.
Claes Lindh
Chief Medical Officer 2022
Born: 1979
Education: MD, Specialist in histopathology and cytology, PhD in prostate cancer pathology from Karolinska Institutet.
Previous positions: Eighteen years’ experience in diagnostic pathology. Region Stockholm, Karolinska University Hospital: Expert pathologist in clinical diagnostics, senior consultant pathologist in urological and gynecological pathology.
Shareholding as of 28 February 2025: 19,000 shares and 318,784 options.
Education: MD, Specialist in histopathology and cytology, PhD in prostate cancer pathology from Karolinska Institutet.
Previous positions: Eighteen years’ experience in diagnostic pathology. Region Stockholm, Karolinska University Hospital: Expert pathologist in clinical diagnostics, senior consultant pathologist in urological and gynecological pathology.
Shareholding as of 28 February 2025: 19,000 shares and 318,784 options.
Arto Järvinen
Chief Technical Officer 2022
Born: 1959
Education: MSc in Electrical Engineering and Applied Physics from Linköping Institute of Technology
Previous positions: ContextVision, 2011–2022, R&D, most recently as CTO (Chief Technology Officer); DNV (Det Norske Veritas), management consultant; Sectra Pronosco A/S, CEO. Järvinen’s expertise includes machine learning, image processing, systems development, operational excellence, MedTech regulations and management of high-tech companies in general.
Shareholding as of 28 February 2025: 11,500 shares and 318,784 options.
Education: MSc in Electrical Engineering and Applied Physics from Linköping Institute of Technology
Previous positions: ContextVision, 2011–2022, R&D, most recently as CTO (Chief Technology Officer); DNV (Det Norske Veritas), management consultant; Sectra Pronosco A/S, CEO. Järvinen’s expertise includes machine learning, image processing, systems development, operational excellence, MedTech regulations and management of high-tech companies in general.
Shareholding as of 28 February 2025: 11,500 shares and 318,784 options.
Johanna Karling
Chief Quality and Regulatory Affairs Officer since 2022
Born: 1963
Education: MSc in chemical engineering, biotechnology, KTH Royal Institute of Technology in Stockholm.
Previous positions: Head of Quality and Regulatory Affairs: ContextVision AB 2018–2022, Bactiguard AB 2010–2014, Aerocrine AB 1999–2010. Since 2014 acting as self-employed consultant for quality and regulatory affairs in the medical technology sector.
Shareholding as of 28 February 2025: 12,851 shares.
Education: MSc in chemical engineering, biotechnology, KTH Royal Institute of Technology in Stockholm.
Previous positions: Head of Quality and Regulatory Affairs: ContextVision AB 2018–2022, Bactiguard AB 2010–2014, Aerocrine AB 1999–2010. Since 2014 acting as self-employed consultant for quality and regulatory affairs in the medical technology sector.
Shareholding as of 28 February 2025: 12,851 shares.